Navigation Links
FDA Approves 1st in New Class of Type 2 Diabetes Drugs
Date:3/29/2013

FRIDAY, March 29 (HealthDay News) -- The first in a new class of type 2 diabetes drugs was approved Friday by the U.S. Food and Drug Administration.

Invokana (canaglifozin) tablets are to be taken, in tandem with a healthy diet and exercise, to improve blood sugar control in adults with type 2 diabetes.

Invokana belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose (sugar) by the kidney and increasing glucose excretions in urine, the FDA said in a news release.

"We continue to advance innovation with the approval of new drug classes that provide additional treatment options for chronic conditions that impact public health," Dr. Mary Parks, director of the division of metabolism and endocrinology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

About 24 million Americans have type 2 diabetes, and it accounts for more than 90 percent of diabetes cases diagnosed in the United States, the FDA said. If blood sugar levels are not carefully controlled, there is an increased risk for serious complications, including heart disease, blindness, and nerve and kidney damage, the agency added.

The FDA approval is based on the findings of nine clinical trials involving more than 10,000 patients. Patients who took the drug showed improvement in hemoglobin A1c levels (a measure of blood sugar control) and fasting blood sugar levels.

Invokana should not be used by people with type 1 diabetes or people with type 2 diabetes who have increased ketones in their blood or urine (diabetic ketoacidosis), severe kidney disease, kidney failure or who are on dialysis, the FDA said.

The agency told drug maker Janssen Pharmaceuticals that it must conduct five post-approval studies of the drug to determine the risk of problems such as heart disease, cancer, pancreatitis, liver abnormalities and pregnancy complications.

The most common side effects of Invokana are vaginal yeast infections and urinary tract infections. It may also cause dizziness and fainting.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about type 2 diabetes.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration, news release, March 29, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
8. FDA Approves New Once-a-Day HIV Pill
9. FDA Approves New Type of Flu Vaccine
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves 1st Skin Patch to Combat Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 1st in New Class of Type 2 Diabetes Drugs
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a point of difference. Eden Activewear is a stand-out company for several differences ... exclusively online and only manufacture on demand, this is called 'Agile' manufacturing - ...
(Date:1/17/2017)... ... 2017 , ... Healthful Balance announces the national release of ... by Ed Stroup, was created to offer the highest quality vitamins and supplements ... service. Healthful Balance products can be purchased online through their website, or can ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s ... of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, ... group of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New ... eye care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment ... Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ... tests and pathology services for evaluating risks of cancer, ... January 13, 2017 from the NASDAQ Listing Qualifications notifying ... requirement of the NASDAQ Stock Market to maintain a ... The letter noted that for the last 10 ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has announced ... report to their offering. ... This unique and comprehensive report, identifies and profiles the leading 200 ... across the globe from the United States and ... China . Profile information for each ...
(Date:1/17/2017)... LONDON , January 17, 2017 ... Review, 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European ... from touchNEUROLOGY, Catherine Amey reports that ...
Breaking Medicine Technology: